Improved Long-Term Prognosis of Dilated Cardiomyopathy With Implementation of Evidenced-Based Medication　– Report From the CHART Studies –

Ushigome, Ryoichi; Sakata, Yasuhiko; Nochioka, Kotaro; Miyata, Satoshi; Miura, Masanobu; Tadaki, Soichiro; Yamauchi, Takeshi; Sato, Kenjiro; Onose, Takeo; Tsuji, Kiichiro; Abe, Ruri; Takahashi, Jun; Shimokawa, Hiroaki

doi:10.1253/circj.cj-14-0939

Cited by 22 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 The prevalence of SCD in HFrEF in Western patients tends to be higher compared with Japanese patients. In MADIT-II, the SCD rate was 10.0% in the conventional therapy group during a mean 20-month follow-up.…”

Section: Underuse Of Icd In Japanmentioning

confidence: 98%

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Satake

Fukuda

Sakata

et al. 2015

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Underuse Of Icd In Japanmentioning

confidence: 98%

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Satake

Fukuda

Sakata

et al. 2015

Circ J

Self Cite

View full text Add to dashboard Cite

“…14 Mortality in both of these studies seems to be better than European cohort in EHFS II registry (20.5% of mortality 'after discharge from initial hospitalization' with 6.7% in-hospital mortality 10,15 ) and Finnish Acute Heart Failure Study registry (27% 'after the day of admission' 16 ) and possibly better than that in US population [The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registry], representing 3.8% in-hospital mortality followed by 8.3% 60-90 day mortality. 17 In addition, prognosis of Japanese heart failure patients has been improved in dilated cardiomyopathy 18 as well as in symptomatic heart failure patients, 19 along with implementation of evidence-based strategies. As far as outpatients are concerned, 1-year mortality in the CHART-2 study was only 4.2%.…”

Section: Epidemiology Of Heart Failure In Japanmentioning

confidence: 99%

Heart failure epidemiology and novel treatments in Japan: facts and numbers

et al. 2016

Self Cite

View full text Add to dashboard Cite

Japan has the highest proportion of older people in the world, 25.9% of the population were aged 65 or above in 2014. Although there have been no population‐based studies that precisely examined the prevalence of heart failure in Japan, one report estimated the number of Japanese outpatients with left ventricular dysfunction was 979, 000 (0.8% of total population), which was projected to increase gradually as the population ages, reaching 1.3 million by 2030. Ischemic etiology was less frequently observed in Japan (31–47%) than in western population (54–57%). The prevalence of HF with preserved ejection fraction was similar between Japan (34–68%) and western countries (34–51%). Non‐cardiac co‐morbidities such as chronic obstructive pulmonary diseases and anemia were observed in 6–9% in Japan and 19–31% in western countries, and 35–58% in Japan and 37–56% in western countries, respectively. The definition of chronic kidney disease widely differed among studies. A relatively good survival prognosis in Japanese patients has been discussed. One‐year mortality after discharge from initial hospitalization was 9–12%, which seems to be better than the western cohort. Although length of stay was remarkably longer in Japan (15–21 days) than western countries (4–9 days), it will have to be shortened, as Japan is now being faced with an upcoming HF pandemic. Some treatments in Japan are not approved outside Japan. Such treatments include carperitide infusion (used in 58% of hospitalized HF), nicorandil infusion (9.6%), and oral pimobendan (5%). More recently, landiolol and tolvaptan have been approved. Although these drugs might have a potential to be an effective therapeutic option, lack of corroborating evidence in many of such treatments would emphasize the need for larger clinical trials.

show abstract

“…26 There have been few reports, however, that examined the temporal trends in clinical outcome of Japanese patients with symptomatic HF in general. In CHART-2 patients ( Figure 5) was determined on the multivariate Cox modeling.…”

Section: Improved Long-term Prognosis Of Japanese Symptomatic Hf Patimentioning

confidence: 99%

Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan　– Report From the CHART Studies –

Ushigome

Sakata

Nochioka

et al. 2015

Circ J

Self Cite

102

View full text Add to dashboard Cite

Improved Long-Term Prognosis of Dilated Cardiomyopathy With Implementation of Evidenced-Based Medication　– Report From the CHART Studies –

Cited by 22 publications

References 23 publications

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Heart failure epidemiology and novel treatments in Japan: facts and numbers

Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan　– Report From the CHART Studies –

Contact Info

Product

Resources

About

Improved Long-Term Prognosis of Dilated Cardiomyopathy With Implementation of Evidenced-Based Medication – Report From the CHART Studies –

Cited by 22 publications

References 23 publications

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Current Status of Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter Defibrillator in Patients With Chronic Heart Failure

Heart failure epidemiology and novel treatments in Japan: facts and numbers

Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan – Report From the CHART Studies –

Contact Info

Product

Resources

About

Improved Long-Term Prognosis of Dilated Cardiomyopathy With Implementation of Evidenced-Based Medication　– Report From the CHART Studies –

Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan　– Report From the CHART Studies –